Get the Stockscreener App
9.93
4.14%
-0.46
Integra Lifesciences Holdings Corp stock is traded at $9.93, with a volume of 302.63K.
It is down -4.14% in the last 24 hours and down -8.46% over the past month.
Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
See More
Previous Close:
$10.39
Open:
$10.27
24h Volume:
302.63K
Relative Volume:
0.42
Market Cap:
$774.70M
Revenue:
$1.53B
Net Income/Loss:
$40.23M
P/E Ratio:
19.86
EPS:
0.5
Net Cash Flow:
$60.93M
1W Performance:
-12.09%
1M Performance:
-8.46%
6M Performance:
-37.71%
1Y Performance:
-54.46%
1-Day Range:
$9.76
$10.30
1-Week Range:
$9.76
$11.47
52-Week Range:
$9.76
$24.36
Integra Lifesciences Holdings Corp Stock (IART) Company Profile
Name
Integra Lifesciences Holdings Corp
Sector
Industry
Phone
(609) 275-0500
Address
1100 CAMPUS ROAD, PRINCETON, NJ
Compare IART vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IART
Integra Lifesciences Holdings Corp
|
9.94 | 809.77M | 1.53B | 40.23M | 60.93M | 0.50 |
|
ABT
Abbott Laboratories
|
111.09 | 196.53B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
372.22 | 146.14B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
92.62 | 122.74B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
71.00 | 107.15B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.01 | 49.45B | 6.07B | 1.06B | 1.34B | 1.8063 |
Integra Lifesciences Holdings Corp Stock (IART) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-25 | Upgrade | Argus | Hold → Buy |
| Dec-02-24 | Initiated | Morgan Stanley | Underweight |
| Oct-07-24 | Upgrade | BTIG Research | Sell → Neutral |
| Jul-30-24 | Downgrade | BTIG Research | Neutral → Sell |
| Jul-30-24 | Downgrade | Citigroup | Neutral → Sell |
| May-07-24 | Downgrade | Oppenheimer | Outperform → Perform |
| May-07-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-03-24 | Upgrade | Citigroup | Sell → Neutral |
| Dec-05-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Nov-14-23 | Initiated | CL King | Buy |
| Aug-24-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-12-23 | Upgrade | Jefferies | Hold → Buy |
| Jun-08-23 | Downgrade | Argus | Buy → Hold |
| May-24-23 | Downgrade | JP Morgan | Neutral → Underweight |
| May-23-23 | Downgrade | Citigroup | Neutral → Sell |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-25-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Downgrade | Truist | Buy → Hold |
| Dec-17-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-08-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-27-20 | Initiated | Citigroup | Neutral |
| Apr-03-20 | Initiated | SunTrust | Buy |
| Jan-07-20 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-19 | Initiated | SunTrust | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Aug-07-18 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jul-26-18 | Upgrade | BTIG Research | Neutral → Buy |
| Jul-02-18 | Downgrade | Citigroup | Buy → Neutral |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Neutral |
| Jan-02-18 | Downgrade | BofA/Merrill | Buy → Neutral |
| Nov-09-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Oct-30-17 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-27-17 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-30-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-02-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jan-13-17 | Reiterated | RBC Capital Mkts | Sector Perform |
| Jan-06-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-12-16 | Initiated | UBS | Buy |
View All
Integra Lifesciences Holdings Corp Stock (IART) Latest News
Integra LifeSciences Holdings Corp. Sees Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Integra LifeSciences Opens Weak with 8.37% Gap Down Amid Market Concerns - Markets Mojo
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Recommendation of "Reduce" by Analysts - MarketBeat
Integra Lifesciences (IART) Analyst Rating Update: Wells Fargo L - GuruFocus
Wells Fargo & Company Issues Pessimistic Forecast for Integra LifeSciences (NASDAQ:IART) Stock Price - MarketBeat
Why Integra LifeSciences (IART) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Integra LifeSciences Holdings Corporation (NASDAQ:IART) Q4 2025 Earnings Call Transcript - Insider Monkey
IART Should I Buy - Intellectia AI
Integra Lifesciences Holdings Corp (IART) Q4 2025 Earnings Call - GuruFocus
Integra LifeSciences Q4 Earnings Call Highlights - Yahoo Finance
Integra LifeSciences (IART) Stock Trades Down, Here Is Why - Finviz
Integra LifeSciences (NASDAQ:IART) Surprises With Q4 CY2025 Sales - Finviz
Q4 2025 Integra Lifesciences Holdings Corp Earnings Call Transcript - GuruFocus
Integra LifeSciences (IART) Beats Q4 Earnings and Revenue Estimates - Yahoo Finance
Integra Lifesciences Holdings Q4 25 Earnings Conference Call At 8:30 AM ET - Nasdaq
Integra LifeSciences (IART) Anticipates Lower Q1 Revenue Than Ex - GuruFocus
INTEGRA LIFESCIENCES HLDGS ($IART) Releases Q4 2025 Earnings - Quiver Quantitative
Integra LifeSciences beats estimates but guides below consensus By Investing.com - Investing.com South Africa
Integra LifeSciences beats estimates but guides below consensus - Investing.com
Integra: Q4 Earnings Snapshot - marketscreener.com
Integra LifeSciences Reports Q4 Loss, Revenue Edges Down - Nasdaq
Integra LifeSciences Reports Fourth Quarter and Full-Year 2025 Financial Results - TradingView
Integra LifeSciences Reports Q4 and Full Year 2025 Financial Results with Operational Progress and 2026 Financial Guidance - Quiver Quantitative
Goodwill hit drives 2025 loss at Integra LifeSciences (NASDAQ: IART) - Stock Titan
Integra takes $511M hit from tariffs, quality and supply issues - Stock Titan
Integra LifeSciences (IART) Reports Earnings Tomorrow: What To Expect - Finviz
CEO Change: Can Integra LifeSciences Holdings Corporation deliver consistent dividendsJuly 2025 Price Swings & AI Forecasted Entry and Exit Points - baoquankhu1.vn
Integra LifeSciences, Enovis, BrightSpring Health Services, IQVIA, and Charles River Laboratories Shares Plummet, What You Need To Know - Finviz
Is Integra LifeSciences Holdings Corporation a cyclical or defensive stockEarnings Beat & Reliable Breakout Forecasts - mfd.ru
1 Russell 2000 Stock to Target This Week and 2 That Underwhelm - Finviz
Integra LifeSciences (IART) to Release Earnings on Thursday - MarketBeat
Integra LifeSciences appoints new CTO and key executives By Investing.com - Investing.com South Africa
Integra LifeSciences Announces Key Executive Leadership Appointments - markets.businessinsider.com
Integra LifeSciences appoints new CTO and key executives - Investing.com
New tech and quality chiefs signal Integra’s next growth push - Stock Titan
VIX Spike: Is Integra LifeSciences Holdings Corporation stock a buy or sellJuly 2025 Drop Watch & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Moderna, Vertex Pharmaceuticals, Integra LifeSciences, Baxter, and Molina Healthcare Shares Are Soaring, What You Need To Know - Yahoo Finance
Is Integra LifeSciences Holdings Corporation stock influenced by commodity prices2025 Risk Factors & Accurate Technical Buy Alerts - mfd.ru
List of 16 Acquisitions by Integra LifeSciences (Feb 2026) - Tracxn
Integra LifeSciences stock faces scrutiny after Reuters report on TruDi system - Investing.com
Integra LifeSciences to Host Fourth Quarter and Full Year 2025 Financial Results Conference Call on February 26, 2026 - Yahoo Finance
Global medical technology firm Integra LifeSciences sets Feb. 26 earnings call - Stock Titan
Investors in Integra LifeSciences Holdings (NASDAQ:IART) have unfortunately lost 84% over the last five years - Yahoo Finance
[Latest] Global Advanced Wound Closure Market Size/Share Worth USD 32.54 Billion by 2035 at a 6.9% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
Bank Watch: Will NANO Nuclear Energy Inc outperform small cap indexes2025 Fundamental Recap & Real-Time Volume Triggers - baoquankhu1.vn
Aug Patterns: What is the earnings history of Integra LifeSciences Holdings CorporationQuarterly Growth Report & Growth Focused Investment Plans - baoquankhu1.vn
Earnings Risk: Will Integra LifeSciences Holdings Corporation benefit from geopolitical trends2025 Breakouts & Breakdowns & High Accuracy Trade Signal Alerts - baoquankhu1.vn
What's Going On With Integra LifeSciences Stock Friday?Integra Lifesciences (NASDAQ:IART) - Benzinga
FDA Alert Targets Integra LifeSciences' MediHoney Wound Products - GuruFocus
Aug Decliners: Is Integra LifeSciences Holdings Corporation a cyclical or defensive stockJuly 2025 Retail & Weekly Hot Stock Watchlists - baoquankhu1.vn
JPM26: Integra resets by fixing supply and riding reimbursement tailwinds - Yahoo Finance
Integra Lifesciences Holdings Corp Stock (IART) Financials Data
Revenue
Net Income
Cash Flow
EPS
Integra Lifesciences Holdings Corp Stock (IART) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GRAVES JEFFREY A | Director |
Nov 05 '25 |
Buy |
11.35 |
9,000 |
102,150 |
41,086 |
| Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL |
Oct 12 '25 |
Option Exercise |
0.00 |
11,965 |
0 |
25,217 |
| Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL |
Mar 11 '25 |
Option Exercise |
0.00 |
2,356 |
0 |
4,391 |
| Singh Harvinder | EVP & PRESIDENT, INTERNATIONAL |
Mar 10 '25 |
Option Exercise |
0.00 |
1,180 |
0 |
2,359 |
1.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):